RedHill Biopharma Ltd. (Nasdaq: RDHL) has been selected to present opaganib’s broad pandemic preparedness and chemical and medical countermeasures potential to U.S. government representatives at the important Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND governmental investment event “Host Directed Therapeutics Industry Day” 29-30 October. Read the RedHill PR: https://bit.ly/3YFPR08
RedHill Biopharma Ltd.
Pharmaceutical Manufacturing
Raleigh עוקבים, NC 6,571
RedHill (NASDAQ: RDHL): a pharmaceutical company focused on proprietary drugs for GI and infectious diseases
עלינו
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
- אתר אינטרנט
-
http://www.redhillbio.com/
קישור חיצוני עבור RedHill Biopharma Ltd.
- תעשייה
- Pharmaceutical Manufacturing
- גודל החברה
- 51-200 עובדים
- משרדים ראשיים
- Raleigh, NC
- סוג
- חברה ציבורית
- הקמה
- 2009
מיקומים
-
הראשי
קבלת הוראות הגעה
8045 Arco Corporate Drive
Suite 120
Raleigh, NC 27617, US
-
קבלת הוראות הגעה
21 Ha’arba’a St.
Tel-Aviv , Israel 6473921, IL
עובדים ב- RedHill Biopharma Ltd.
-
Gilead Raday
-
Rob Cohen
Sr. Director, Communications, RedHill Biopharma Ltd.
-
Steven Thomasian
Vice President Global Supply Chain and Manufacturing @ RedHill Biopharma | Strategic Sourcing, Process Improvement, Cost Savings and Commercial…
-
Alexandra Okmian Sanderovich
Senior Business Development and Investor Relations Manager at RedHill Biopharma Ltd.
עדכונים
-
RedHill Biopharma Ltd. (Nasdaq: RDHL) and Duke University School of Medicine enter collaboration to develop opaganib as a medical countermeasure for phosgene injury, aimed toward advanced U.S. government-sponsored FDA Animal Rule development. Read the RedHill PR: https://bit.ly/4dV8txh
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
redhillbio.com
-
We’re excited to be a part of the American College of Gastroenterology Conference #ACG2024 in Philadelphia, PA, October 25-30. Stop by and visit us at the RedHill Biopharma booth 679! Visit https://lnkd.in/e9truVu for more info and follow ACG for conference updates.
ACG's Annual Scientific Meeting & Postgraduate Course
https://acgmeetings.gi.org
-
RedHill Biopharma’s (Nasdaq: RDHL) opaganib selected by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) for joint development & funding as a medical countermeasure to treat exposure to Ebola virus disease. Read RedHill’s PR: https://bit.ly/4eCnGVg
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
redhillbio.com
-
RedHill Biopharma Ltd. (Nasdaq: RDHL) and Medi-Cal (California Department of Health Care Services' Medicaid healthcare program) deal maintains Talicia reimbursement without prior authorization and a $0 copay for 15 million Californians. Read the RedHill PR: https://bit.ly/4eFwGII
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
redhillbio.com
-
RedHill Biopharma Ltd.’s (Nasdaq: RDHL) opaganib granted new U.S. Patent and Trademark Office (USPTO) patent for identification of a novel biomarker of #coronavirus pneumonia - prognostic for potential opaganib efficacy in treating #COVID19, valid through 2041. Read the RedHill PR: https://bit.ly/4gIrO7D
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
redhillbio.com
-
We’re excited to be a part of the American College of Gastroenterology Conference #ACG2024 in Philadelphia, PA, October 25-30. Stop by and visit us at the RedHill Biopharma booth 679! Visit https://lnkd.in/e9truVu for more info and follow ACG for conference updates.
ACG's Annual Scientific Meeting & Postgraduate Course
https://acgmeetings.gi.org
-
Last day of the Texas Society for Gastroenterology and Endoscopy (TSGE) Conference in Austin, TX. Stop by and visit us at the RedHill Biopharma booth! Follow TSGE for conference updates.
Texas Society for Gastroenterology and Endoscopy - TSGE | LinkedIn
linkedin.com
-
We’re excited to be a part of the Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Conference in National Harbor, MD, September 12-14. Stop by and visit us at the RedHill Biopharma booth! Follow GHAPP for conference updates.
-
RedHill Biopharma’s (Nasdaq:RDHL) Talicia positioned first-line for the treatment of H. pylori infection in the new American College of Gastroenterology (ACG) clinical guideline. Read the RedHill PR: https://bit.ly/3XyeRWm
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
redhillbio.com